Brian T. Jankowitz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Brian T. Jankowitz has a total of 101 co-authors. Here are the top co-authors by number of shared publications:
- Jan-Karl Burkhardt
Department of Neurosurgery, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA
4 shared publications - Mohamed M. Salem
Department of Neurosurgery, Hospital of the University of Pennsylvania, Penn Medicine, Philadelphia, Pennsylvania, USA
4 shared publications - Ashutosh Prabhakar Jadhav
Department of Neurology and Neurosurgery, University of Pittsburgh School of Medicine, PA (A.P.J.).
3 shared publications - Tudor G. Jovin
Department of Neurology, Cooper Medical School of Rowan University, Camden, NJ (T.G.J.).
3 shared publications - Ajith J. Thomas
Department of Neurosurgery, Cooper University Health Care, Camden, New Jersey, USA
2 shared publications - Bradley A. Gross
Neurosurgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
2 shared publications
Latest Publications
- 24 August 2026
- Published by Springer Nature in Neurosurgical Review
- Vol. 49 (1) , 535
Navigating the use of artificial intelligence in the peer review process: Cautionary pearls from the editorial board
Peer review remains a cornerstone of academic publishing, underpinning the integrity and credibility of the scientific literature. High-quality peer review is both a human art and a learned skill, requiring an understanding of study design, critical appraisal and subject-specific expertise. However, the rapid expansion of scientific publishing has placed increasing strain on the peer review ecosystem, contributing to reviewer fatigue, delays, and variability in review quality. Recent advances in artificial intelligence (AI) offer potential opportunities to enhance the efficiency and consistency of peer review, but their integration into editorial workflows requires careful consideration. In this editorial, we explore the evolving role of peer review, the challenges facing the current ecosystem, and the potential – yet constrained – role of AI, from the perspective of the Editorial Board of Neurosurgical Review.
- 24 August 2026
- Published by Springer Nature in Neurosurgical Review
- Vol. 49 (1) , 535
Navigating the use of artificial intelligence in the peer review process: Cautionary pearls from the editorial board
Peer review remains a cornerstone of academic publishing, underpinning the integrity and credibility of the scientific literature. High-quality peer review is both a human art and a learned skill, requiring an understanding of study design, critical appraisal and subject-specific expertise. However, the rapid expansion of scientific publishing has placed increasing strain on the peer review ecosystem, contributing to reviewer fatigue, delays, and variability in review quality. Recent advances in artificial intelligence (AI) offer potential opportunities to enhance the efficiency and consistency of peer review, but their integration into editorial workflows requires careful consideration. In this editorial, we explore the evolving role of peer review, the challenges facing the current ecosystem, and the potential – yet constrained – role of AI, from the perspective of the Editorial Board of Neurosurgical Review.
- 23 October 2024
- Published by Springer Nature in Neurosurgical Review
- Vol. 47 (1) , 1-5
The delicate nature of a constructive peer review: pearls from the editorial board
Peer review stands as a cornerstone of academic publishing, especially in the era of evidence-based neurosurgery – the scientific literature relies on proficient peer reviewers. Providing a constructive peer review is an art and learned skill that requires knowledge of study design and expertise in the neurosurgical subspeciality. Peer reviewers guard against arbitrary decision-making and are essential in ensuring that published manuscripts are of the highest quality. However, there remains a scarcity in the formal training relating to the peer review process. The objective of this article is therefore to shed light on this process through the lens of the Editorial Board. We encourage our invited peer reviewers to make use of this guide when appraising potential manuscripts.
- 23 October 2024
- Published by Springer Nature in Neurosurgical Review
- Vol. 47 (1) , 1-5
The delicate nature of a constructive peer review: pearls from the editorial board
Peer review stands as a cornerstone of academic publishing, especially in the era of evidence-based neurosurgery – the scientific literature relies on proficient peer reviewers. Providing a constructive peer review is an art and learned skill that requires knowledge of study design and expertise in the neurosurgical subspeciality. Peer reviewers guard against arbitrary decision-making and are essential in ensuring that published manuscripts are of the highest quality. However, there remains a scarcity in the formal training relating to the peer review process. The objective of this article is therefore to shed light on this process through the lens of the Editorial Board. We encourage our invited peer reviewers to make use of this guide when appraising potential manuscripts.
- Open Access
- 1 January 2024
- Published by Wolters Kluwer Health in Stroke: Vascular and Interventional Neurology
- Vol. 4 (1)
Aristotle‐Only Direct Aspiration First‐Pass Technique (AO‐ADAPT) for Endovascular Mechanical Thrombectomy: A Technical Series of a Novel Technique Demonstrating Safety and Efficacy
Background: The introduction of soft, large‐profile microwires has improved aspiration catheter delivery for intracranial large‐vessel occlusions. The Aristotle‐only direct aspiration first‐pass technique (AO‐ADAPT) uses the Aristotle 24 microwire to deliver a large‐bore aspiration catheter to the target occlusion without a microcatheter. We characterized rates of technical success achieved using this technique for mechanical aspiration thrombectomy. Methods: A retrospective review of prospectively collected thrombectomy databases at 4 academic institutions identified patients undergoing procedures in which AO‐ADAPT was used. Patient demographics, clinical considerations, technical details, and radiographic outcomes were collected. Rates of successful aspiration catheter delivery without adjunctive devices and of successful reperfusion (Thrombolysis in Cerebral Infarction≥2B) were collected. Results: Forty‐five patients met inclusion criteria (mean age 72.2±13.2 years, 62.2% female; 71.1% M1 occlusions). With a first‐line AO‐ADAPT approach, 42/45 (93.3%) patients achieved Thrombolysis in Cerebral Infarction≥2B reperfusion, with first‐pass recanalization in 26/45 (57.8%). We delivered the aspiration catheter to the target occlusion without adjunctive device in 35/45 (77.8%) patients. Of these, 29 (82.9%) underwent successful contact aspiration. This entire cohort (64.4% of the population) achieved Thrombolysis in Cerebral Infarction≥2B, with a mean time to reperfusion of 16 minutes and a first‐pass recanalization rate of 66%. Of the 16 patients who did not achieve successful AO‐ADAPT reperfusion, 6 needed a microcatheter for aspiration catheter delivery but underwent successful contact aspiration, 6 achieved microcatheter‐free delivery but needed a stentriever for final recanalization, and 4 required both microcatheter for delivery and stentriever for final recanalization. No intracranial vascular complications occurred during the procedures; 1 patient (2.2%) experienced symptomatic intracranial hemorrhage secondary to reperfusion injury. Conclusion: The AO‐ADAPT approach to mechanical thrombectomy safely and effectively achieved reperfusion for patients with large‐vessel occlusions, with first‐pass success and successful recanalization rates comparable with other techniques. For most cases in this series, this technique obviated the need for a microcatheter and/or stentriever.
- 1 January 2024
- Published by Wolters Kluwer Health in Stroke: Vascular and Interventional Neurology
- Vol. 4 (1)
Open AccessAristotle‐Only Direct Aspiration First‐Pass Technique (AO‐ADAPT) for Endovascular Mechanical Thrombectomy: A Technical Series of a Novel Technique Demonstrating Safety and Efficacy
Background: The introduction of soft, large‐profile microwires has improved aspiration catheter delivery for intracranial large‐vessel occlusions. The Aristotle‐only direct aspiration first‐pass technique (AO‐ADAPT) uses the Aristotle 24 microwire to deliver a large‐bore aspiration catheter to the target occlusion without a microcatheter. We characterized rates of technical success achieved using this technique for mechanical aspiration thrombectomy. Methods: A retrospective review of prospectively collected thrombectomy databases at 4 academic institutions identified patients undergoing procedures in which AO‐ADAPT was used. Patient demographics, clinical considerations, technical details, and radiographic outcomes were collected. Rates of successful aspiration catheter delivery without adjunctive devices and of successful reperfusion (Thrombolysis in Cerebral Infarction≥2B) were collected. Results: Forty‐five patients met inclusion criteria (mean age 72.2±13.2 years, 62.2% female; 71.1% M1 occlusions). With a first‐line AO‐ADAPT approach, 42/45 (93.3%) patients achieved Thrombolysis in Cerebral Infarction≥2B reperfusion, with first‐pass recanalization in 26/45 (57.8%). We delivered the aspiration catheter to the target occlusion without adjunctive device in 35/45 (77.8%) patients. Of these, 29 (82.9%) underwent successful contact aspiration. This entire cohort (64.4% of the population) achieved Thrombolysis in Cerebral Infarction≥2B, with a mean time to reperfusion of 16 minutes and a first‐pass recanalization rate of 66%. Of the 16 patients who did not achieve successful AO‐ADAPT reperfusion, 6 needed a microcatheter for aspiration catheter delivery but underwent successful contact aspiration, 6 achieved microcatheter‐free delivery but needed a stentriever for final recanalization, and 4 required both microcatheter for delivery and stentriever for final recanalization. No intracranial vascular complications occurred during the procedures; 1 patient (2.2%) experienced symptomatic intracranial hemorrhage secondary to reperfusion injury. Conclusion: The AO‐ADAPT approach to mechanical thrombectomy safely and effectively achieved reperfusion for patients with large‐vessel occlusions, with first‐pass success and successful recanalization rates comparable with other techniques. For most cases in this series, this technique obviated the need for a microcatheter and/or stentriever.
- 1 November 2023
- Published by Wolters Kluwer Health in Stroke: Vascular and Interventional Neurology
- Vol. 3 (S2)
Abstract 169: Antiplatelet regimens after pseudoaneurysm embolization with phosphorylcholine coated flow diverters: a series of 180 cases
Introduction: Indications for flow diversion for the treatment of cerebral aneurysms have increased remarkably in recent years.1 This has been particularly useful for aneurysms that are difficult to treat via endosaccular or open approaches, such as pseudoaneurysms.2 Flow diversion, however, typically requires dual antiplatelet therapy (DAPT), which can contribute to greater morbidity particularly in patients with ruptured aneurysms or other comorbidities.3 The third‐generation iteration of the Pipeline Embolization Device (PED) incorporates Shield technology, a phosphorylcholine coating designed to reduce thrombogenicity via mimicry of native cell membranes.4 In light of this reduced thrombogenicity, there have been reports of early transition to single antiplatelet therapy (SAPT), or other variations on DAPT, in patients treated with PED Shield. We therefore aim to characterize the antiplatelet regimens, and associated thromboembolic/hemorrhagic outcomes, utilized in patients with aneurysms treated with PED Shield. Methods: Factors including demographics, comorbidities, rupture status, devices placed, and antiplatelet regimen, among others, were collected. Follow‐up data including aneurysm thromboembolic complication, hemorrhagic complication, new neurological deficit, aneurysm occlusion, and in‐stent thrombosis were also recorded. Results: One‐hundred and eighty patients were included in analysis, 18 of which were acutely ruptured. One hundred and sixty‐two patients had a single device placed, while the remaining had two devices placed. Three patients were maintained on SAPT post‐procedurally (aspirin or clopidogrel), with two additional patients treated with SAPT plus an anticoagulant for other purposes. One hundred and seventy‐two patients were maintained on DAPT, most commonly aspirin/clopidogrel (115), followed by aspirin/ticagrelor (40), and aspirin/prasugrel (16). Seven patients had strokes of any kind, three of which were unrelated to the treatment territory, and two of the remaining 4 were non‐compliant with antiplatelet therapy. One patient had a new intraparenchymal hemorrhage, but no appreciable deficit. Of the 135 patients with 6‐month follow‐up, 77 had complete aneurysm occlusion, and 116 demonstrated no in‐stent thrombosis. Conclusion: We demonstrate herein the similar safety profile and efficacy of PED Shield with varying antiplatelet regimens, including SAPT in isolated cases.
- 1 November 2023
- Published by Wolters Kluwer Health in Stroke: Vascular and Interventional Neurology
- Vol. 3 (S2)
Abstract 169: Antiplatelet regimens after pseudoaneurysm embolization with phosphorylcholine coated flow diverters: a series of 180 cases
Introduction: Indications for flow diversion for the treatment of cerebral aneurysms have increased remarkably in recent years.1 This has been particularly useful for aneurysms that are difficult to treat via endosaccular or open approaches, such as pseudoaneurysms.2 Flow diversion, however, typically requires dual antiplatelet therapy (DAPT), which can contribute to greater morbidity particularly in patients with ruptured aneurysms or other comorbidities.3 The third‐generation iteration of the Pipeline Embolization Device (PED) incorporates Shield technology, a phosphorylcholine coating designed to reduce thrombogenicity via mimicry of native cell membranes.4 In light of this reduced thrombogenicity, there have been reports of early transition to single antiplatelet therapy (SAPT), or other variations on DAPT, in patients treated with PED Shield. We therefore aim to characterize the antiplatelet regimens, and associated thromboembolic/hemorrhagic outcomes, utilized in patients with aneurysms treated with PED Shield. Methods: Factors including demographics, comorbidities, rupture status, devices placed, and antiplatelet regimen, among others, were collected. Follow‐up data including aneurysm thromboembolic complication, hemorrhagic complication, new neurological deficit, aneurysm occlusion, and in‐stent thrombosis were also recorded. Results: One‐hundred and eighty patients were included in analysis, 18 of which were acutely ruptured. One hundred and sixty‐two patients had a single device placed, while the remaining had two devices placed. Three patients were maintained on SAPT post‐procedurally (aspirin or clopidogrel), with two additional patients treated with SAPT plus an anticoagulant for other purposes. One hundred and seventy‐two patients were maintained on DAPT, most commonly aspirin/clopidogrel (115), followed by aspirin/ticagrelor (40), and aspirin/prasugrel (16). Seven patients had strokes of any kind, three of which were unrelated to the treatment territory, and two of the remaining 4 were non‐compliant with antiplatelet therapy. One patient had a new intraparenchymal hemorrhage, but no appreciable deficit. Of the 135 patients with 6‐month follow‐up, 77 had complete aneurysm occlusion, and 116 demonstrated no in‐stent thrombosis. Conclusion: We demonstrate herein the similar safety profile and efficacy of PED Shield with varying antiplatelet regimens, including SAPT in isolated cases.
- Open Access
- 30 July 2023
- Published by BMJ
- Vol. 15 (Suppl 1) , A83.2-A84
E-015 Comparing woven endobridge (WEB) treatment outcomes between ruptured and unruptured aneurysms: a systematic review and meta-analysis
Introduction The Woven EndoBridge (WEB) device is a nitinol mesh intrasaccular device that does not require the need for antiplatelet therapy, making it an appealing option for wide-necked aneurysms regardless of its rupture status. However, current literature has limited power to evaluate the differences in the efficacy and safety of WEB embolization for ruptured versus unruptured aneurysms. Methods We performed a systematic review between January 1960 and October 2022, of all the studies in which the WEB device was used for the treatment of ruptured and unruptured aneurysms. The primary efficacy outcome was adequate occlusion after WEB implantation. The safety outcome was a composite of intraprocedural and device-related post-operative ischemic and hemorrhagic events. The data was analyzed with a random-effects meta-analysis of proportions, and statistical heterogeneity was assessed with I2 statistics. Results A total of 22 studies with 858 unique aneurysms were included in our analysis. Of those, 486 (56%) aneurysms were ruptured, and 372 (44%) were unruptured. The adequate occlusion rate at the last follow-up was similar between ruptured (81% [95% CI 75–86%; I2=27%]) and unruptured (83% [95% CI 77–88%; I2=8%]; p subgroup difference=.24) aneurysms. The rate of safety events was similar between ruptured (8% [95% CI 6–12%; I2=32%]) and unruptured (6% [95% CI 3–9%; I2=0%]; p subgroup difference=.16) aneurysms. Conclusion This systematic review with meta-analysis found that WEB embolization for ruptured and unruptured aneurysms is safe and effective, with similar radiographic and safety outcomes in both scenarios. The use of the WEB device may reduce the need for open surgical procedures for complex aneurysms, leading to shorter hospital stays and faster recovery times for patients. The evidence of our findings suggests that this device can be a valuable option for complex ruptured and unruptured aneurysms. Forest plot for adequate occlusion Forest plot for safety events Disclosures S. Mannam: None. I. Matache: None. J. Vivanco-Suarez: None. S. Ajmera: None. G. Sioutas: None. M. Salem: None. B. Jankowitz: None. J. Burkhardt: None. V. Srinivasan: None.
- 30 July 2023
- Published by BMJ
- Vol. 15 (Suppl 1) , A83.2-A84
Open AccessE-015 Comparing woven endobridge (WEB) treatment outcomes between ruptured and unruptured aneurysms: a systematic review and meta-analysis
Introduction The Woven EndoBridge (WEB) device is a nitinol mesh intrasaccular device that does not require the need for antiplatelet therapy, making it an appealing option for wide-necked aneurysms regardless of its rupture status. However, current literature has limited power to evaluate the differences in the efficacy and safety of WEB embolization for ruptured versus unruptured aneurysms. Methods We performed a systematic review between January 1960 and October 2022, of all the studies in which the WEB device was used for the treatment of ruptured and unruptured aneurysms. The primary efficacy outcome was adequate occlusion after WEB implantation. The safety outcome was a composite of intraprocedural and device-related post-operative ischemic and hemorrhagic events. The data was analyzed with a random-effects meta-analysis of proportions, and statistical heterogeneity was assessed with I2 statistics. Results A total of 22 studies with 858 unique aneurysms were included in our analysis. Of those, 486 (56%) aneurysms were ruptured, and 372 (44%) were unruptured. The adequate occlusion rate at the last follow-up was similar between ruptured (81% [95% CI 75–86%; I2=27%]) and unruptured (83% [95% CI 77–88%; I2=8%]; p subgroup difference=.24) aneurysms. The rate of safety events was similar between ruptured (8% [95% CI 6–12%; I2=32%]) and unruptured (6% [95% CI 3–9%; I2=0%]; p subgroup difference=.16) aneurysms. Conclusion This systematic review with meta-analysis found that WEB embolization for ruptured and unruptured aneurysms is safe and effective, with similar radiographic and safety outcomes in both scenarios. The use of the WEB device may reduce the need for open surgical procedures for complex aneurysms, leading to shorter hospital stays and faster recovery times for patients. The evidence of our findings suggests that this device can be a valuable option for complex ruptured and unruptured aneurysms. Forest plot for adequate occlusion Forest plot for safety events Disclosures S. Mannam: None. I. Matache: None. J. Vivanco-Suarez: None. S. Ajmera: None. G. Sioutas: None. M. Salem: None. B. Jankowitz: None. J. Burkhardt: None. V. Srinivasan: None.
- Open Access
- 1 July 2023
- Published by Wolters Kluwer Health in Stroke: Vascular and Interventional Neurology
- Vol. 3 (4)
Transradial Versus Transfemoral Access for Mechanical Thrombectomy: A Systematic Review and Meta‐Analysis
Background: In patients undergoing mechanical thrombectomy for acute ischemic stroke, a few studies have compared transradial access (TRA) to transfemoral access (TFA) with inconsistent results. We conducted this systematic review and meta‐analysis to provide comprehensive evidence regarding the comparison of procedural and clinical outcomes of TRA versus TFA in patients with acute ischemic stroke undergoing mechanical thrombectomy. Methods: We performed a comprehensive literature search of 4 electronic databases from inception until May 1, 2022. After title and full text screening, relevant data were extracted and then analyzed. For outcomes that constituted continuous data, the mean difference between the 2 groups and its SD were pooled. For outcomes that constituted dichotomous data, the frequency of events and the total number of patients in each group were pooled as odds ratio (OR) between the 2 groups. Results: Nine observational studies were included in this meta‐analysis. The population of the studies was homogenous comprising a total of 2161 patients undergoing mechanical thrombectomy, including 446 patients via TRA and 1715 patients via TFA. There were no significant differences across the 2 groups in terms of successful recanalization (OR, 0.83 [95% CI, 0.55–1.25]; P =0.36), complete recanalization (OR 1.16 [95% CI, 0.50–2.68]; P =0.73), favorable functional outcomes (OR, 0.86 [95% CI, 0.53–1.41]; P =0.56), first‐pass reperfusion (OR, 0.88 [95% CI, 0.64–1.19]; P =0.41), number of passes (mean difference, 0.12 [95% CI, −0.18 to 0.42]; P =0.43), access‐to‐reperfusion time (mean difference, −3.92 minutes [95% CI, −9.49 to 1.65]; P =0.17), or symptomatic intracranial hemorrhage (OR, 0.86 [95% CI, 0.47–1.57]; P =0.62). However, access site complications were significantly less frequent in the TRA group as compared with the TFA group (OR, 0.18 [95% CI, 0.06–0.51; P =0.001). Conclusion: In patients undergoing mechanical thrombectomy for acute ischemic stroke, the collective evidence suggests that TRA seems to result in lower rates of access site complications than TFA without significant compromise in other clinical or procedural metrics. Randomized or prospective studies are warranted to confirm these results.
- 1 July 2023
- Published by Wolters Kluwer Health in Stroke: Vascular and Interventional Neurology
- Vol. 3 (4)
Open AccessTransradial Versus Transfemoral Access for Mechanical Thrombectomy: A Systematic Review and Meta‐Analysis
Background: In patients undergoing mechanical thrombectomy for acute ischemic stroke, a few studies have compared transradial access (TRA) to transfemoral access (TFA) with inconsistent results. We conducted this systematic review and meta‐analysis to provide comprehensive evidence regarding the comparison of procedural and clinical outcomes of TRA versus TFA in patients with acute ischemic stroke undergoing mechanical thrombectomy. Methods: We performed a comprehensive literature search of 4 electronic databases from inception until May 1, 2022. After title and full text screening, relevant data were extracted and then analyzed. For outcomes that constituted continuous data, the mean difference between the 2 groups and its SD were pooled. For outcomes that constituted dichotomous data, the frequency of events and the total number of patients in each group were pooled as odds ratio (OR) between the 2 groups. Results: Nine observational studies were included in this meta‐analysis. The population of the studies was homogenous comprising a total of 2161 patients undergoing mechanical thrombectomy, including 446 patients via TRA and 1715 patients via TFA. There were no significant differences across the 2 groups in terms of successful recanalization (OR, 0.83 [95% CI, 0.55–1.25]; P =0.36), complete recanalization (OR 1.16 [95% CI, 0.50–2.68]; P =0.73), favorable functional outcomes (OR, 0.86 [95% CI, 0.53–1.41]; P =0.56), first‐pass reperfusion (OR, 0.88 [95% CI, 0.64–1.19]; P =0.41), number of passes (mean difference, 0.12 [95% CI, −0.18 to 0.42]; P =0.43), access‐to‐reperfusion time (mean difference, −3.92 minutes [95% CI, −9.49 to 1.65]; P =0.17), or symptomatic intracranial hemorrhage (OR, 0.86 [95% CI, 0.47–1.57]; P =0.62). However, access site complications were significantly less frequent in the TRA group as compared with the TFA group (OR, 0.18 [95% CI, 0.06–0.51; P =0.001). Conclusion: In patients undergoing mechanical thrombectomy for acute ischemic stroke, the collective evidence suggests that TRA seems to result in lower rates of access site complications than TFA without significant compromise in other clinical or procedural metrics. Randomized or prospective studies are warranted to confirm these results.
- 1 March 2023
- Published by Wolters Kluwer Health in Stroke: Vascular and Interventional Neurology
- Vol. 3 (S1)
Abstract Number ‐ 39: Comparison of Clinical and Radiographic Efficacy of Particles versus nBCA/Onyx in MMA Embolization for cSDH
Introduction: Middle meningeal artery (MMA) embolization has emerged as a minimally invasive alternative to open surgery for treatment of chronic subdural hematoma (cSDH). Different embolic materials are utilized in this procedure per operators’ discretion; however, limited data currently exists regarding the clinical and radiographic efficacy of these embolic materials, with available studies lumping Onyx and N‐Butyl cyanoacrylate (n‐BCA) into a single group of liquid embolic material. Methods: Series of consecutive patients undergoing MMA embolization (MMAE) for cSDH at 2 North American centers (2019‐2021) were included. The primary outcomes included cSDH radiographic resolution of cSDH with at least 50% reduction of hematoma thickness to be considered treatment success. Clinical outcomes were defined as the proportion of patients requiring additional unplanned surgical intervention. These outcomes compared between the particles group, the liquid group which were further subdivided into the n‐BCA and Onyx groups. Results: Overall, 185 patients undergoing 198 MMAE procedures (median age 72 years, 27.5% women) were included in this analysis. In this cohort, 42.6% of the procedures were performed utilizing particles embolic material, while n‐BCA and Onyx were utilized in 29.5% and 26.8% of procedures, respectively. On last follow‐up imaging (median 3.5 months), ≥ 50% reduction in hematoma thickness was achieved in 67.7%, 71.1%, and 72.3% in the particles, Onyx and the n‐BCA group, respectively (p = 0.2). There were no differences in the proportion of patients requiring additional unplanned surgery between the groups (p = 0.6). Similarly, there was no difference in procedural complications between the 3 embolic materials groups. Conclusions: MMAE for cSDH utilizing particles and liquid embolic materials (including Onyx and n‐BCA) appears to have an overall equivalent safety and efficacy profiles in cSDH treatment. Further studies with larger sample sizes and longer follow‐up are warranted.
- 1 March 2023
- Published by Wolters Kluwer Health in Stroke: Vascular and Interventional Neurology
- Vol. 3 (S1)
Abstract Number ‐ 39: Comparison of Clinical and Radiographic Efficacy of Particles versus nBCA/Onyx in MMA Embolization for cSDH
Introduction: Middle meningeal artery (MMA) embolization has emerged as a minimally invasive alternative to open surgery for treatment of chronic subdural hematoma (cSDH). Different embolic materials are utilized in this procedure per operators’ discretion; however, limited data currently exists regarding the clinical and radiographic efficacy of these embolic materials, with available studies lumping Onyx and N‐Butyl cyanoacrylate (n‐BCA) into a single group of liquid embolic material. Methods: Series of consecutive patients undergoing MMA embolization (MMAE) for cSDH at 2 North American centers (2019‐2021) were included. The primary outcomes included cSDH radiographic resolution of cSDH with at least 50% reduction of hematoma thickness to be considered treatment success. Clinical outcomes were defined as the proportion of patients requiring additional unplanned surgical intervention. These outcomes compared between the particles group, the liquid group which were further subdivided into the n‐BCA and Onyx groups. Results: Overall, 185 patients undergoing 198 MMAE procedures (median age 72 years, 27.5% women) were included in this analysis. In this cohort, 42.6% of the procedures were performed utilizing particles embolic material, while n‐BCA and Onyx were utilized in 29.5% and 26.8% of procedures, respectively. On last follow‐up imaging (median 3.5 months), ≥ 50% reduction in hematoma thickness was achieved in 67.7%, 71.1%, and 72.3% in the particles, Onyx and the n‐BCA group, respectively (p = 0.2). There were no differences in the proportion of patients requiring additional unplanned surgery between the groups (p = 0.6). Similarly, there was no difference in procedural complications between the 3 embolic materials groups. Conclusions: MMAE for cSDH utilizing particles and liquid embolic materials (including Onyx and n‐BCA) appears to have an overall equivalent safety and efficacy profiles in cSDH treatment. Further studies with larger sample sizes and longer follow‐up are warranted.
- 6 August 2020
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 41 (9) , 1647-1651
Emergent Premedication for Contrast Allergy Prior to Endovascular Treatment of Acute Ischemic Stroke
BACKGROUND AND PURPOSE: Management of contrast media allergies may lead to treatment delays in patients with acute ischemic stroke undergoing endovascular therapy. The optimal premedication strategy remains unclear. The aim of this report was to analyze our experience with emergent administration of premedication regimens before endovascular therapy. MATERIALS AND METHODS: We retrospectively reviewed prospective data for all patients undergoing endovascular therapy from 2012 to 2019 at an academic comprehensive stroke center. Records of patients with documented contrast allergy were reviewed and analyzed. Data collected included stroke risk factors and characteristics, historical contrast reaction details, premedication regimens administered, and signs or symptoms of allergic reaction developing post-endovascular therapy. Hospital arrival time to endovascular therapy was compared with that in those who did not have a history of contrast allergy. RESULTS: We analyzed 1521 patients undergoing endovascular therapy; 60 (4%) had documented contrast allergies and constituted the study cohort. The median age was 73 years (interquartile range, 66–81 years), and 65% were women. The median time from premedication to contrast was 24 minutes (interquartile range, 0–36 minutes). Forty-three patients (72%) proceeded directly to endovascular therapy; in 17 patients, the first contrast exposure was CTA. Time from hospital arrival to endovascular therapy was not slower for patients with documented allergies (96 versus 134 minutes, P = .32). No patients experienced a contrast media reaction. CONCLUSIONS: In a single-institution cohort study of 60 consecutive patients with documented contrast allergies undergoing endovascular therapy with emergent premedication en route to (or in) the neuroangiography suite, no patients experienced allergic symptoms. This pragmatic approach may be safe for patients who have documented contrast media allergies.
- 6 August 2020
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 41 (9) , 1647-1651
Emergent Premedication for Contrast Allergy Prior to Endovascular Treatment of Acute Ischemic Stroke
BACKGROUND AND PURPOSE: Management of contrast media allergies may lead to treatment delays in patients with acute ischemic stroke undergoing endovascular therapy. The optimal premedication strategy remains unclear. The aim of this report was to analyze our experience with emergent administration of premedication regimens before endovascular therapy. MATERIALS AND METHODS: We retrospectively reviewed prospective data for all patients undergoing endovascular therapy from 2012 to 2019 at an academic comprehensive stroke center. Records of patients with documented contrast allergy were reviewed and analyzed. Data collected included stroke risk factors and characteristics, historical contrast reaction details, premedication regimens administered, and signs or symptoms of allergic reaction developing post-endovascular therapy. Hospital arrival time to endovascular therapy was compared with that in those who did not have a history of contrast allergy. RESULTS: We analyzed 1521 patients undergoing endovascular therapy; 60 (4%) had documented contrast allergies and constituted the study cohort. The median age was 73 years (interquartile range, 66–81 years), and 65% were women. The median time from premedication to contrast was 24 minutes (interquartile range, 0–36 minutes). Forty-three patients (72%) proceeded directly to endovascular therapy; in 17 patients, the first contrast exposure was CTA. Time from hospital arrival to endovascular therapy was not slower for patients with documented allergies (96 versus 134 minutes, P = .32). No patients experienced a contrast media reaction. CONCLUSIONS: In a single-institution cohort study of 60 consecutive patients with documented contrast allergies undergoing endovascular therapy with emergent premedication en route to (or in) the neuroangiography suite, no patients experienced allergic symptoms. This pragmatic approach may be safe for patients who have documented contrast media allergies.
- Open Access
- 28 May 2020
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 41 (6) , 1037-1042
Multicenter Postmarket Analysis of the Neuroform Atlas Stent for Stent-Assisted Coil Embolization of Intracranial Aneurysms
BACKGROUND AND PURPOSE: The Neuroform Atlas is a new microstent to assist coil embolization of intracranial aneurysms that recently gained FDA approval. We present a postmarket multicenter analysis of the Neuroform Atlas stent. MATERIALS AND METHODS: On the basis of retrospective chart review from 11 academic centers, we analyzed patients treated with the Neuroform Atlas after FDA exemption from January 2018 to June 2019. Clinical and radiologic parameters included patient demographics, aneurysm characteristics, stent parameters, complications, and outcomes at discharge and last follow-up. RESULTS: Overall, 128 aneurysms in 128 patients (median age, 62 years) were treated with 138 stents. Risk factors included smoking (59.4%), multiple aneurysms (27.3%), and family history of aneurysms (16.4%). Most patients were treated electively (93.7%), and 8 (6.3%) underwent treatment within 2 weeks of subarachnoid hemorrhage. Previous aneurysm treatment failure was present in 21% of cases. Wide-neck aneurysms (80.5%), small aneurysm size (P < .0001) and rupture status during treatment (P = .03). CONCLUSIONS: This multicenter analysis provides a real-world safety and efficacy profile for the treatment of intracranial aneurysms with the Neuroform Atlas stent.
- 28 May 2020
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 41 (6) , 1037-1042
Open AccessMulticenter Postmarket Analysis of the Neuroform Atlas Stent for Stent-Assisted Coil Embolization of Intracranial Aneurysms
BACKGROUND AND PURPOSE: The Neuroform Atlas is a new microstent to assist coil embolization of intracranial aneurysms that recently gained FDA approval. We present a postmarket multicenter analysis of the Neuroform Atlas stent. MATERIALS AND METHODS: On the basis of retrospective chart review from 11 academic centers, we analyzed patients treated with the Neuroform Atlas after FDA exemption from January 2018 to June 2019. Clinical and radiologic parameters included patient demographics, aneurysm characteristics, stent parameters, complications, and outcomes at discharge and last follow-up. RESULTS: Overall, 128 aneurysms in 128 patients (median age, 62 years) were treated with 138 stents. Risk factors included smoking (59.4%), multiple aneurysms (27.3%), and family history of aneurysms (16.4%). Most patients were treated electively (93.7%), and 8 (6.3%) underwent treatment within 2 weeks of subarachnoid hemorrhage. Previous aneurysm treatment failure was present in 21% of cases. Wide-neck aneurysms (80.5%), small aneurysm size (P < .0001) and rupture status during treatment (P = .03). CONCLUSIONS: This multicenter analysis provides a real-world safety and efficacy profile for the treatment of intracranial aneurysms with the Neuroform Atlas stent.
- Open Access
- 27 December 2018
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 40 (1) , 51-58
Infarct Volume Predicts Hospitalization Costs in Anterior Circulation Large-Vessel Occlusion Stroke
BACKGROUND AND PURPOSE: Anterior circulation large-vessel occlusion stroke, one of the most devastating stroke subtypes, is associated with substantial economic burden. We aimed to identify predictors of increased acute care hospitalization costs associated with anterior circulation large-vessel occlusion stroke. MATERIALS AND METHODS: Comprehensive cost-tracking software was used to calculate acute care hospitalization costs for patients with anterior circulation large-vessel occlusion stroke admitted July 2012 to October 2014. Patient demographics and stroke characteristics were analyzed, including final infarct volume on follow-up neuroimaging. Predictors of hospitalization costs were determined using multivariable linear regression including subgroup cost analyses by treatment technique (endovascular, IV tPA-only, and no reperfusion therapy) and sensitivity analyses incorporating patients initially excluded due to early withdrawal of care. RESULTS: Three hundred forty-one patients (median age, 69 years; interquartile range, 57–80 years; median NIHSS score, 16; interquartile range, 13–21) were included in our primary analysis. Final infarct volume, parenchymal hematoma, baseline NIHSS score, ipsilateral carotid stenosis, age, and obstructive sleep apnea were significant predictors of acute care hospitalization costs. Final infarct volume alone accounted for 20.87% of the total cost variance. Additionally, final infarct volume was consistently the strongest predictor of increased cost in primary, subgroup, and sensitivity analyses. CONCLUSIONS: Final infarct volume was the strongest predictor of increased hospitalization costs in anterior circulation large-vessel occlusion stroke. Acute stroke therapies that reduce final infarct volume may not only improve clinical outcomes but may also prove cost-effective.
- 27 December 2018
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 40 (1) , 51-58
Open AccessInfarct Volume Predicts Hospitalization Costs in Anterior Circulation Large-Vessel Occlusion Stroke
BACKGROUND AND PURPOSE: Anterior circulation large-vessel occlusion stroke, one of the most devastating stroke subtypes, is associated with substantial economic burden. We aimed to identify predictors of increased acute care hospitalization costs associated with anterior circulation large-vessel occlusion stroke. MATERIALS AND METHODS: Comprehensive cost-tracking software was used to calculate acute care hospitalization costs for patients with anterior circulation large-vessel occlusion stroke admitted July 2012 to October 2014. Patient demographics and stroke characteristics were analyzed, including final infarct volume on follow-up neuroimaging. Predictors of hospitalization costs were determined using multivariable linear regression including subgroup cost analyses by treatment technique (endovascular, IV tPA-only, and no reperfusion therapy) and sensitivity analyses incorporating patients initially excluded due to early withdrawal of care. RESULTS: Three hundred forty-one patients (median age, 69 years; interquartile range, 57–80 years; median NIHSS score, 16; interquartile range, 13–21) were included in our primary analysis. Final infarct volume, parenchymal hematoma, baseline NIHSS score, ipsilateral carotid stenosis, age, and obstructive sleep apnea were significant predictors of acute care hospitalization costs. Final infarct volume alone accounted for 20.87% of the total cost variance. Additionally, final infarct volume was consistently the strongest predictor of increased cost in primary, subgroup, and sensitivity analyses. CONCLUSIONS: Final infarct volume was the strongest predictor of increased hospitalization costs in anterior circulation large-vessel occlusion stroke. Acute stroke therapies that reduce final infarct volume may not only improve clinical outcomes but may also prove cost-effective.